1. Home
  2. DXR vs CTSO Comparison

DXR vs CTSO Comparison

Compare DXR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daxor Corporation

DXR

Daxor Corporation

HOLD

Current Price

$13.82

Market Cap

61.1M

Sector

Health Care

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.69

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXR
CTSO
Founded
1970
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DXR
CTSO
Price
$13.82
$0.69
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$25.00
$5.38
AVG Volume (30 Days)
2.6K
124.8K
Earning Date
02-27-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
3.46
N/A
EPS
0.36
N/A
Revenue
$66,306.00
$36,979,520.00
Revenue This Year
N/A
$7.26
Revenue Next Year
N/A
$9.78
P/E Ratio
$38.33
N/A
Revenue Growth
N/A
23.89
52 Week Low
$6.55
$0.60
52 Week High
$14.15
$1.61

Technical Indicators

Market Signals
Indicator
DXR
CTSO
Relative Strength Index (RSI) 62.36 47.73
Support Level $12.00 $0.61
Resistance Level $12.90 $0.77
Average True Range (ATR) 0.38 0.06
MACD 0.10 0.00
Stochastic Oscillator 97.95 53.86

Price Performance

Historical Comparison
DXR
CTSO

About DXR Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: